+285.2%
LIN vs MRNA
+1,040.1%
-755.0%
-32.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | -6.8% | +7.0% | +0.4% |
| 7D | +2.0% | +9.8% | -7.8% | +1.7% |
| 30D | +7.9% | +11.5% | -3.6% | +7.5% |
| 3M | +6.3% | +319.4% | -313.1% | +0.1% |
| 6M | +6.5% | +361.5% | -355.0% | -0.5% |
| YTD | +23.6% | +750.6% | -727.0% | +11.9% |
| 1Y | +25.7% | +913.0% | -887.3% | +12.8% |
| 3Y | +35.6% | +258.1% | -222.5% | +24.9% |
| 5Y | +65.9% | +9.6% | +56.3% | +57.6% |
| All | +285.2% | +1,040.1% | -755.0% | +234.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling